		<div class="wpcnt">
			<div class="wpa">
				<span class="wpa-about">Advertisements</span>
				<div class="u top_amp">
							<amp-ad width="300" height="265"
		 type="pubmine"
		 data-siteid="111265417"
		 data-section="2">
		</amp-ad>
				</div>
			</div>
		</div><p><a href="http://londonglossy.com/wp-content/uploads/2010/12/nhs-rejects-drug-for-breast-cancer.jpg"><img class="alignnone size-full" title="A drug to treat advanced breast cancer has been rejected for use on the NHS" src="http://londonglossy.com/wp-content/uploads/2010/12/min-nhs-rejects-drug-for-breast-cancer.jpg" alt="A drug to treat advanced breast cancer has been rejected for use on the NHS"/></a></p>
<p>A drug to treat advanced breast cancer has been rejected for use on the NHS just days before US regulators decide its fate in America.</p>
<p>The National Institute for Health and Clinical Excellence (Nice) said Avastin (bevacizumab) offers &#8220;limited and uncertain benefit&#8221; for patients and does not lead to any significant extension of life.</p>
<p>Nice appraised Avastin in combination with a type of chemotherapy for treating breast cancer which has spread around the body.</p>
<p>It comes as the Food and Drug Administration (FDA) in the US prepares to announce its decision, by December 17, on the use of Avastin in breast cancer.</p>
<p>In July, the FDA&#8217;s advisory panel voted in favour of revoking approval for the drug, saying it did not offer a &#8220;clinically meaningful&#8221; benefit.</p>
<p>European regulators are also reviewing the benefits of Avastin for breast cancer in light of fresh clinical data. The drug is licensed in the UK for bowel and kidney cancer but has not received approval from Nice for either of these diseases. It is also licensed for lung cancer.</p>
<p>Sir Andrew Dillon, chief executive of Nice, said: &#8220;We know that it&#8217;s immensely important for breast cancer patients whose disease has spread to prolong their lives as much as possible. Unfortunately, we did not receive any evidence from the manufacturer to show that bevacizumab can significantly lengthen a patient&#8217;s life or, importantly, offer a better quality of life than existing treatments.</p>
<p>&#8220;Although the data seemed to show that the drug may slow the growth and spread of the cancer, the size of this effect varied between studies. Furthermore, it was extremely unclear that the benefits in terms of slowing tumour growth translated into benefits on overall survival, which is what really matters for patients.&#8221;</p>
<p>The guidance from Nice is now subject to appeal. Nice&#8217;s panel reviewed clinical trials on the use of Avastin for breast cancer but found no significant evidence of extra months of survival. Further evidence on selected groups of breast cancer patients did not display any &#8220;robust proof&#8221; they would gain benefit compared with other patients who had advanced breast cancer, Nice said.</p>
<p>The total average cost per patient of Avastin is more than £33,000, according to figures submitted by manufacturer Roche.</p>
			<div style="padding-bottom:15px;" class="wordads-tag" data-slot-type="belowpost">
				<div id="atatags-dynamic-belowpost-68ee337222e91">
					<script type="text/javascript">
						window.getAdSnippetCallback = function () {
							if ( false === ( window.isWatlV1 ?? false ) ) {
								// Use Aditude scripts.
								window.tudeMappings = window.tudeMappings || [];
								window.tudeMappings.push( {
									divId: 'atatags-dynamic-belowpost-68ee337222e91',
									format: 'belowpost',
								} );
							}
						}

						if ( document.readyState === 'loading' ) {
							document.addEventListener( 'DOMContentLoaded', window.getAdSnippetCallback );
						} else {
							window.getAdSnippetCallback();
						}
					</script>
				</div>
			</div>
Discover more from London Glossy Post
Subscribe to get the latest posts sent to your email.
